Clinical Trial Update: Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating eltrombopag as first-line therapy for Primary Immune Thrombocytopenia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Renata PLC | Conditions: Primary Immune Thrombocytopenia | Phase 1, Phase 2 | Status: RECRUITING